CYP26A1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL694638	0.50	10/20
SCHEMBL202436	0.56	9/20
Talarozole (SCHEMBL721201)	1.00	8/20
SCHEMBL727915	0.50	8/20
SCHEMBL727916	0.64	7/20
SCHEMBL726740	1.00	6/20
SCHEMBL667347	0.69	6/20
SCHEMBL799753	0.58	6/20
Irtemazole (SCHEMBL636285)	0.57	6/20
SCHEMBL527839	0.51	6/20
Tamibarotene (SCHEMBL36207)	1.00	5/20
SCHEMBL165750	1.00	5/20
SCHEMBL165751	1.00	5/20
SCHEMBL738495	0.77	5/20
SCHEMBL201689	0.67	5/20
SCHEMBL763475	0.56	5/20
SCHEMBL501417	0.55	5/20
SCHEMBL367301	0.49	5/20
Hydrochloric Acid (SCHEMBL412293)	0.49	5/20
SCHEMBL551813	0.84	4/20

Clinical trials — most relevant to CYP26A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Tamoxifen Prediction Study in Patients With ER+ Breast Cancer	PHASE4	UNKNOWN
Tamoxifen Citrate in Patients With Breast Cancer	PHASE3	UNKNOWN
Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients	PHASE3	COMPLETED
The Prevalence of Vitamin D Deficiency and Effects of Vitamin D Supplementation in HIV-1 Infected Patients	PHASE2	UNKNOWN
Androgen Reduction in Congenital Adrenal Hyperplasia	PHASE2	WITHDRAWN
Vitamin D Supplementation in Cirrhotic Patients	PHASE2	COMPLETED
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer	PHASE2	RECRUITING
Efavirenz for Patients With Alzheimer's Disease	PHASE1	COMPLETED
The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH	PHASE1	UNKNOWN
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer	PHASE1	COMPLETED
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors	PHASE1	COMPLETED
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot	PHASE1	COMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva	nan	COMPLETED
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease	nan	COMPLETED
Replacement of Vitamin D in Patients With Active Tuberculosis	nan	COMPLETED
Connecting Breath and Mind for CYP With Long COVID	nan	UNKNOWN
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING
EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients	nan	COMPLETED
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis	nan	COMPLETED
Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum	nan	COMPLETED
Pharmacogenomic Profiling of Pediatric Patients	nan	COMPLETED
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk	nan	COMPLETED
Mutation Analysis of 17α-Hydroxylase	nan	UNKNOWN
DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements	nan	COMPLETED
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics	nan	COMPLETED
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline	nan	COMPLETED
Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting.	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP26A1 binder may also engage these)

Protein	Name	Similarity
O55127	—	1.000	O55127 →
Q9PUB4	—	1.000	Q9PUB4 →
O93323	—	0.998	O93323 →
P79739	—	0.992	P79739 →
Q08D50	—	0.987	Q08D50 →
E1BHJ4	—	0.985	E1BHJ4 →
G3V7X8	—	0.985	G3V7X8 →
B6SSW8	—	0.984	B6SSW8 →
Q6EIG3	—	0.984	Q6EIG3 →
CYP26B1	Cytochrome P450 26B1	0.983	landscape →
B9G934	—	0.981	B9G934 →
A5BFI4	—	0.981	A5BFI4 →
Q0DS59	—	0.981	Q0DS59 →
Q9ZV29	—	0.980	Q9ZV29 →
Q50EK0	—	0.979	Q50EK0 →
Q9ZV28	—	0.979	Q9ZV28 →
Q811W2	—	0.979	Q811W2 →
A0A517FNC4	—	0.979	A0A517FNC4 →
A0A9Y1LLN2	—	0.979	A0A9Y1LLN2 →
Q9LVY7	—	0.979	Q9LVY7 →
Q5CCK3	—	0.978	Q5CCK3 →
B5BSX1	—	0.978	B5BSX1 →
O23051	—	0.977	O23051 →
I1H7R8	—	0.977	I1H7R8 →
Q5CCK1	—	0.976	Q5CCK1 →
I1GQE7	—	0.976	I1GQE7 →
A0A5A4DV62	—	0.976	A0A5A4DV62 →
A2ZHX7	—	0.976	A2ZHX7 →
A0A067E1K2	—	0.976	A0A067E1K2 →
A0AAW1NEA3	—	0.976	A0AAW1NEA3 →